A patient's time to progression on first-line CDK4/6 inhibitor therapy acts as an informal biomarker. A shorter duration, such as 14 months, is viewed by experts as "not so great" and indicates a degree of underlying endocrine resistance that influences subsequent treatment strategies.

The ELEGANT trial uses a "switch strategy," introducing elicestrin only after 2-5 years of standard therapy. This design pragmatically adapts to the evolving clinical landscape where CDK4/6 inhibitors are now standard initial treatment, ensuring the trial's relevance by testing the drug in a post-CDK4/6 inhibitor setting.

While PI3K pathway alterations are linked to a poor prognosis, real-world data provides reassurance for a common clinical dilemma. Patients with co-mutations in both ESR1 and PI3K pathways still achieve significant benefit from elacestrant monotherapy, with progression-free survival (5.2-6.3 months) comparable to the overall population in the pivotal EMERALD trial.

Post-approval studies of the oral SERD elacestrant confirm its clinical benefit in ESR1-mutant breast cancer. However, this real-world evidence also reveals a new insight: patients who have both an ESR1 and a PIK3CA mutation tend to have a shorter time on treatment, suggesting that the PIK3CA mutation may drive resistance to this therapy.

Three major trials (RIGHT Choice, PADMA, OMBRE) definitively show that starting with a CDK4/6 inhibitor plus endocrine therapy is superior to upfront chemotherapy for newly diagnosed, symptomatic metastatic breast cancer. This approach provides better progression-free survival without the toxicity of chemotherapy and, critically, does not result in a slower time to response.

Contrary to the norm where real-world outcomes are worse than in controlled trials, real-world data for the oral SERD elacestrant shows efficacy as good as, or even better than, the pivotal EMERALD study. This unusual finding significantly bolsters confidence in the drug's broad clinical utility across a less-selected patient population.

Despite the appeal of stopping treatment, a key insight from clinical practice is that patients' most critical question remains which therapy offers the longest period of remission, often overriding factors like treatment duration and oral-only options.

Data from multiple trials (EMERALD, VERITEC-2) reveal that the duration of a patient's response to a prior CDK4/6 inhibitor acts as a key predictive biomarker. Patients who benefited from CDK4/6 inhibitors for longer periods (e.g., >12-18 months) subsequently experienced a significantly greater progression-free survival benefit from oral SERD therapy.

Data from the MONARCH-E and NATALY trials show that the benefit of adjuvant CDK4/6 inhibitors like abemaciclib and ribociclib persists and even increases after patients complete their 2-3 year treatment course. This sustained "carryover effect" suggests a lasting impact on disease biology rather than just temporary suppression.